Increase in Prevalence of Cervical Cancer and Rise in Government Funding Are New Revenue Pockets for the Cervical Cancer Screening Market
The report segments the cervical cancer screening market is segmented on the basis of test types, end users, and geographies. Based on test type, the cervical cancer screening market is segmented into pap tests and HPV/co tests. Among both, the HPV/co-test is estimated to grow at a higher CAGR during the forecast period. This growth can largely be attributed to the growing incidences of cervical cancer, higher consistency and effectiveness of HPV tests and co-tests that reduce the annual cost of the treatment.
Sample Request @ Sample Report on Cervical Cancer Screening Market
On the basis end users, cervical cancer screening market is classified into hospitals, laboratories, and independent physicians’ offices and clinics. The laboratories segment accounted for the largest share in 2014, while the hospitals segment is estimated to grow at a faster rate due to the increasing volume of patients in hospitals.
On the basis of geography, the cervical cancer screening market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW). In 2014, North America accounted for the largest share of the cervical cancer screening market. On the other hand, Asia-Pacific is expected to register a higher growth rate during the forecast period, owing to huge investment opportunities in this region.
Growing incidences of cervical cancer among sexually active women and the increased risk of HPV infection among them and favorable government initiatives and funding to increase disease awareness are driving the cervical cancer screening market. The market will be further driven by the growing adoption and awareness towards the use of molecular diagnostic assays and kits. However, the availability of HPV vaccines, uncertain reimbursement rates, and changes in regulatory guidelines are hindering the growth of the cervical cancer screening market.
cervical cancer screening market
